Identifying Driver Genes Mutations with Clinical Significance in Thyroid Cancer
Source abstract
Abstract
Advances in technology are enabling gene mutations in papillary thyroid carcinoma (PTC) to be analyzed and clinical outcomes, such as recurrence, to be predicted. To date, the most common genetic mutation in PTC is in BRAF kinase (BRAF). However, whether mutations in other genes coincide with those in BRAF remains to be clarified. The aim of this study was to find mutations in other genes that co-exist with mutated BRAF, and to analyze their frequency and clinical relevance in PTC. Clinical and genetic data were collected from 213 PTC patients with a total of 36,572 mutation sites in 735 genes. After matching with genes from PTC entries in a global database (NCBI Gene), 69 genes with mutations in coding regions were chosen for further study. Through frequency-based analysis, we identified commonly mutated genes co-existing with mutated BRAF and, using the mutation count correlation matrix (MCCM) method, analyzed their incidence according to age and gender. We designed Chord diagrams to reveal gene relationships concerning age and gender, and found that mutations in ALK, ATM, COL1A1, MSTIR, PRKCA, and WNK1 most commonly coincide with mutated BRAF, followed by APC, AURKA, and AURKB. These findings provide further insight into the genetic profile of PTC.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Thyroid Cancer Diagnosis and Treatment
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (22)
Show source-provided references
1. Genetics, genomics, and cancer risk assessment
2. Targeted therapy in cancer10.1007/s00280-015-2861-1 ↗
3. Thyroid cancer10.1016/S0140-6736(16)30172-6 ↗
4. Historical evolution of thyroid surgery: From the ancient times to the dawn of the 21st century10.1007/s00268-010-0580-7 ↗
5. Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer10.1038/s41467-019-10680-5 ↗
6. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer10.1001/jama.2013.3190 ↗
7. Signaling pathways in thyroid cancer and their therapeutic implications10.14740/jocmr2480w ↗
8. BRAF mutation in papillary thyroid carcinoma10.1093/jnci/95.8.625 ↗
9. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation10.1038/sj.onc.1200206 ↗
10. Effect of BRAF mutational status on expression profiles in conventional papillary thyroid carcinomas10.1186/1471-2164-16-S1-S6 ↗
11. Geographic influences in the global rise of thyroid cancer10.1038/s41574-019-0263-x ↗
12. Efficacy of convalescent plasma in relation to dose of ebola virus antibodies: To the editor10.1056/NEJMc1609116 ↗
13. AACR project genie: Powering precision medicine through an international consortium10.1158/2159-8290.CD-17-0151 ↗
14. Role of BRAF in thyroid oncogenesis10.1158/1078-0432.CCR-11-1155 ↗
15. Association between BRAF and RAS mutations, and RET rearrangements and the clinical features of papillary thyroid cancer
16. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: A meta-analysis10.1210/jc.2012-2104 ↗
17. D’Cruz etal, BRAFV600E mutation in papillary thyroid carcinoma: Significant association with node metastases and extra thyroidal invasion10.1007/s12022-011-9184-5 ↗
18. American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer10.1089/thy.2015.0020 ↗
19. Genomic and transcriptomic characteristics according to size of papillary thyroid microcarcinoma10.3390/cancers12051345 ↗
20. NCBI, “Home-Gene-NCBI,” 2016 [Online]. https://www.ncbi.nlm.nih.gov/gene.
21. Circlize implements and enhances circular visualization in R10.1093/bioinformatics/btu393 ↗
22. BRAF V600E and risk stratification of thyroid microcarcinoma: A multicenter pathological and clinical study10.1038/modpathol.2015.92 ↗